Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.84 |
| ▸ | FLT1 | P17948 | 5/20 | 0.73 |
| ▸ | FLT4 | P35916 | 5/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435814 | 0.86 | KDR (0.87) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL274763 | 0.84 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2435019 | 0.84 | KDR (0.62) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2436244 | 0.84 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2435183 | 0.84 | KDR (0.83) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2437488 | 0.81 | KDR (0.78) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL29525857 | 0.80 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2433509 | 0.80 | KDR (1.00) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2748156 | 0.79 | KDR (0.76) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL4548655 | 0.79 | KDR (0.68) | KDRFLT1FLT4RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | KDR 4875/4885FLT1 4884/4885FLT4 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.